Advertisement
Advertisement
QURE
uniQure N.V.
47.13
USDSponsored
+2.00
+4.44%
Aug 13, 15:49 UTC -4
Open
QURE Earnings Reports
Positive Surprise Ratio
QURE beat 24 of 43 last estimates.
56%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
uniQure N.V. earnings per share and revenue
On Jul 29, 2026, QURE reported earnings of -1.22 USD per share (EPS) for Q2 26, missing the estimate of -0.84 USD, resulting in a -45.12% surprise. Revenue reached 5.84 million, compared to an expected 5.58 million, with a 4.74% difference. The market reacted with a +9.30% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.89
Actual
-$0.77
Surprise
+13.99%
CorMedix Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
$0.24
Actual
$0.28
Surprise
+19.44%
Cabaletta Bio, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.34
Surprise
+10.69%
Abeona Therapeutics Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.23
Actual
-$0.35
Surprise
-49.19%
Fate Therapeutics, Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.25
Surprise
+8.49%
ADC Therapeutics SA
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.21
Actual
-$0.11
Surprise
+49.12%
Pelthos Therapeutics Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$3.10
Actual
-$6.62
Surprise
-112.99%
MiNK Therapeutics, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.61
Actual
-$0.62
Surprise
-1.31%
PDS Biotechnology Corporation Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.18
Surprise
-35.75%
Biofrontera Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.05
Surprise
+53.31%
FAQ
What were uniQure N.V.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, uniQure N.V. reported EPS of -$1.22, missing estimates by -45.12%, and revenue of $5.84M, 4.74% above expectations.
How did the market react to uniQure N.V.'s Q2 2026 earnings?
The stock price moved up 9.3%, changed from $36.66 before the earnings release to $40.07 the day after.
When is uniQure N.V. expected to report next?
The next earning report is scheduled for --.
What are the forecasts for uniQure N.V.'s next earnings report?
Based on --
analysts, uniQure N.V. is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement